Filopanti, M <br/><br/>
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.  [electronic resource] 

 -  The pharmacogenomics journal  Oct 2008 
 - 357-63 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-1150 
<br/><br/><label>Standard No.: </label>10.1038/tpj.2008.1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenoma--drug therapy<br/>Adult<br/>Alleles<br/>Cabergoline<br/>Cross-Sectional Studies<br/>Dopamine Agonists--therapeutic use<br/>Ergolines--therapeutic use<br/>Female<br/>Gene Frequency<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>Pituitary Neoplasms--drug therapy<br/>Polymorphism, Genetic<br/>Prolactin--metabolism<br/>Receptors, Dopamine D2--genetics<br/>Retrospective Studies